RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Income before tax

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndIncome before tax (Million USD)YoY (%)
Dec 31, 2024249-94.33%
Dec 31, 20234,380+3.48%
Dec 31, 20224,232+55.01%
Dec 31, 20212,730-12.40%
Dec 31, 20203,117+123.44%
Dec 31, 20191,395+132.39%
Dec 31, 2018600-3925.87%
Dec 31, 2017-16-76.71%
Dec 31, 2016-67-87.92%
Dec 31, 2015-558-24.10%
Dec 31, 2014-735-24.71%
Dec 31, 2013-976+7783.99%
Dec 31, 2012-12-120.48%
Dec 31, 201160

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)